Johnson & Johnson (JNJ)vsStevanato Group SpA (STVN)
JNJ
Johnson & Johnson
$254.66
+3.99%
HEALTHCARE · Cap: $613.02B
STVN
Stevanato Group SpA
$18.39
-0.27%
HEALTHCARE · Cap: $4.98B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 7908% more annual revenue ($96.36B vs $1.20B). JNJ leads profitability with a 21.8% profit margin vs 11.7%. STVN appears more attractively valued with a PEG of 3.57. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
STVN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.1%
Fair Value
$136.12
Current Price
$254.66
$118.54 premium
Margin of Safety
+64.0%
Fair Value
$43.34
Current Price
$18.39
$24.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Premium valuation, high expectations priced in
2.9% earnings growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : STVN
The primary concerns for STVN are P/E Ratio, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while STVN is a value play — different risk/reward profiles.
STVN carries more volatility with a beta of 0.78 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 46/100), backed by strong 21.8% margins. STVN offers better value entry with a 64.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a premier global supplier of advanced drug delivery systems, catering to the pharmaceutical and biotechnology industries with innovative, high-quality glass and polymer packaging solutions for injectable medications. With a strong focus on quality, sustainability, and the integration of cutting-edge technology, the company is strategically positioned to capitalize on the increasing demand within the biopharmaceutical sector. Stevanato's commitment to enhancing the efficiency and reliability of drug administration underscores its potential as a compelling investment choice for institutional investors seeking exposure to healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?